# Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct01986569/  
OnCo record `nct01986569` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of FES PET in Breast cancer, run by Asan Medical Center, completed.

## Summary

Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT01986569 by Asan Medical Center, with 93 participants recorded, started 2013-11 and reaching its primary completion in 2016-11. Interventions recorded: [18F]fluoroestradiol (FES). Conditions recorded: Recurrent Breast Cancer, Stage IV Breast Cancer.

Linked to the technology FES PET because the registry's title names it ("18f fluoroestradiol pet") and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01986569
- Phase: 3
- Setting: A Phase III, Open Label, Non-randomized, Single Center Study to Evaluate Diagnostic Accuracy and Safety of Fluorine-18 (18F) Fluoroestradiol PET/CT in the Assessment of ER Status of Recurrent or Metastatic Lesions in Patients With Breast Cancer
- Sponsor: Asan Medical Center
- Enrolled: 93

## Sources

- ClinicalTrials.gov NCT01986569: https://clinicaltrials.gov/study/NCT01986569

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [FES PET (oestrogen receptor imaging)](https://onco.cc/technologies/fes-pet/)

---
JSON: https://onco.cc/api/v1/entities/nct01986569.json